Search

Dear Editor, Two histone deacetylase (HDAC) inhibitors, vorinostat and romidepsin, have been approved by regulatory agencies in parts of the world for the treatment of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS) based on positive phase II trial results.[[1]] Panobinostat has activity in MF/SS, and is approved in the U.S.A. for the treatment of myeloma.[3] HDAC inhibitors are of different classes, with vorinostat and panobinostat both hydroxamic acids with pan-HDAC inhibitor activity, and romidepsin a cyclic peptide with specificity to class I HDAC. Here, we now review the use of HDAC inhibitors in the treatment of patients with MF/SS at our institution, and examine TTNT for three HDAC inhibitors: romidepsin, vorinostat and panobinostat. GLO:F03/01feb20:bjd18522-fig-0001.jpg PHOTO (COLOR): Time to next treatment for patients with mycosis fungoides (MF) or Sézary syndrome (SS) treated with histone deacetylase inhibitors (N = 82). gl. [Extracted from the article] more...